Search Results
Sep 08, 2026, 08:00 ET Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference
except as required by law.Genprex, Inc.(877) 774-GNPX (4679)GNPX Investor [email protected] GNPX Media ContactKalyn Dabbs
More news about: Genprex, Inc.
Aug 18, 2026, 07:00 ET Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy
events, except as required by law.Genprex, Inc.(877) 774-GNPX (4679)GNPX Investor [email protected]GNPX Media ContactKalyn Dabbs
More news about: Genprex, Inc.
Aug 03, 2026, 07:00 ET Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies
except as required by law.Genprex, Inc.(877) 774-GNPX (4679)GNPX Investor [email protected]GNPX Media ContactKalyn Dabbs
More news about: Genprex, Inc.
Jun 22, 2026, 09:00 ET Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer
except as required by law.Genprex, Inc.(877) 774-GNPX (4679)GNPX Investor [email protected] GNPX Media ContactKalyn Dabbs
More news about: Genprex, Inc.
Jun 17, 2026, 09:00 ET Genprex to Participate at BIO International Convention 2026
except as required by law.Genprex, Inc.(877) 774-GNPX (4679)GNPX Investor [email protected] GNPX Media ContactKalyn Dabbs
More news about: Genprex, Inc.
May 26, 2026, 08:00 ET Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting
events, except as required by law.Genprex, Inc.(877) 774-GNPX (4679)GNPX Investor [email protected]GNPX Media ContactKalyn Dabbs
More news about: Genprex, Inc.
May 14, 2026, 08:00 ET Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
except as required by law.Genprex, Inc.(877) 774-GNPX (4679)GNPX Investor [email protected]GNPX Media ContactKalyn Dabbs
More news about: Genprex, Inc.
Apr 30, 2026, 08:00 ET Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
events, except as required by law.Genprex, Inc.(877) 774-GNPX (4679)GNPX Investor [email protected]GNPX Media ContactKalyn Dabbs
More news about: Genprex, Inc.
Apr 28, 2026, 07:00 ET Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
except as required by law.Genprex, Inc.(877) 774-GNPX (4679)GNPX Investor [email protected] GNPX Media ContactKalyn Dabbs
More news about: Genprex, Inc.
Apr 22, 2026, 07:00 ET Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting
except as required by law.Genprex, Inc.(877) 774-GNPX (4679)GNPX Investor [email protected]GNPX Media ContactKalyn Dabbs
More news about: Genprex, Inc.
Apr 21, 2026, 07:00 ET Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy
except as required by law.Genprex, Inc.(877) 774-GNPX (4679)GNPX Investor [email protected] GNPX Media ContactKalyn Dabbs
More news about: Genprex, Inc.
Apr 20, 2026, 07:00 ET Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
except as required by law.Genprex, Inc.(877) 774-GNPX (4679)GNPX Investor [email protected] GNPX Media ContactKalyn Dabbs
More news about: Genprex, Inc.
Mar 18, 2026, 07:00 ET Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting
except as required by law.Genprex, Inc.(877) 774-GNPX (4679)GNPX Investor [email protected] GNPX Media ContactKalyn Dabbs
More news about: Genprex, Inc.
Mar 10, 2026, 07:00 ET Genprex to Participate at BIO Europe Spring 2026
except as required by law.Genprex, Inc.(877) 774-GNPX (4679)GNPX Investor [email protected]GNPX Media ContactKalyn Dabbs
More news about: Genprex, Inc.
Feb 23, 2026, 08:00 ET Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer
except as required by law.Genprex, Inc.(877) 774-GNPX (4679)GNPX Investor [email protected]GNPX Media ContactKalyn Dabbs
More news about: Genprex, Inc.
Feb 11, 2026, 17:31 ET EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
Biopharma (HKG: 9926), Summit Therapeutics (NASDAQ: SMMT), J INTS BIO, Merus (NASDAQ: MRUS), Merck (NYSE: MRK), Kelun-Biotech (HKG: 6990), Genprex (NASDAQ: GNPX), Cullinan Oncology (NASDAQ: CGEM), Taiho Pharma, CSPC Pharmaceutical (HKG: 1093), AbbVie (NYSE: ABBV), Teligene, Bristol–Myers Squibb (NYSE: BMY), SystImmune,
More news about: DelveInsight Business Research, LLP
Feb 10, 2026, 08:00 ET Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
except as required by law.Genprex, Inc.(877) 774-GNPX (4679)GNPX Investor [email protected] GNPX Media ContactKalyn Dabbs
More news about: Genprex, Inc.
Jan 07, 2026, 07:00 ET Genprex Provides Clinical Update on Diabetes Gene Therapy Program
except as required by law.Genprex, Inc.(877) 774-GNPX (4679)GNPX Investor [email protected]GNPX Media ContactKalyn Dabbs
More news about: Genprex, Inc.
Jan 06, 2026, 07:00 ET Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies
except as required by law.Genprex, Inc.(877) 774-GNPX (4679)GNPX Investor [email protected] GNPX Media ContactKalyn Dabbs
More news about: Genprex, Inc.
Nov 24, 2025, 07:00 ET Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer
except as required by law.Genprex, Inc.(877) 774-GNPX (4679)GNPX Investor [email protected] GNPX Media ContactKalyn Dabbs
More news about: Genprex, Inc.
Nov 19, 2025, 07:00 ET Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials
Inc.(877) 774-GNPX (4679) GNPX Investor Relations [email protected] GNPX Media ContactKalyn
More news about: Genprex, Inc.
Nov 18, 2025, 07:00 ET Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
Inc.(877) 774-GNPX (4679) GNPX Investor Relations [email protected] GNPX Media ContactKalyn
More news about: Genprex, Inc.
Nov 04, 2025, 07:00 ET Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
Inc.(877) 774-GNPX (4679) GNPX Investor Relations [email protected] GNPX Media ContactKalyn
More news about: Genprex, Inc.
Oct 28, 2025, 11:19 ET Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules
Inc.(877) 774-GNPX (4679) GNPX Investor Relations [email protected] GNPX Media Contact
More news about: Genprex, Inc.
Oct 28, 2025, 07:00 ET Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Inc.(877) 774-GNPX (4679) GNPX Investor Relations [email protected] GNPX Media ContactKalyn
More news about: Genprex, Inc.